Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Open Label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and PK/PD Profile of Multiple Subcutaneous Injection of KN057 in Male Patients with Severe Hemophilia a or Moderate-to-Severe Hemophilia B with or Without Inhibitors

NCT06747416 is registered in ClinicalTrials.gov with Suzhou Alphamab Co., Ltd. as lead sponsor.

NCT NCT06747416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06747416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Open Label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and PK/PD Profile of Multiple Subcutaneous Injection of KN057 in Male Patients with Severe Hemophilia a or Moderate-to-Severe Hemophilia B with or Without Inhibitors
Lead sponsor
Suzhou Alphamab Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 2, 2025
Completion date
December 31, 2026
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a and b